Novartis
NEWS
ARS Pharmaceuticals, Intarcia Therapeutics and Taysha Gene Therapies this week got stark reminders of the difficulties in getting treatments through the regulator’s approval process.
Novartis announced the Phase III PSMAfore trial of Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer met its primary endpoint.
With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.
Novartis’ canakinumab failed again in non-small cell lung cancer while Anixa Biosciences, Palisade Bio and Genexine kicked off new trials.
Novartis released results from the Phase III CANOPY-A trial, showing that its canakinumab candidate failed to meet its primary efficacy endpoint in adult NSCLC patients.
Two patients receiving Novartis’ SMA gene therapy Zolgensma have died from acute liver failure, the company reported Thursday.
BeiGene and Novartis’ unresectable hepatocellular carcinoma treatment, Tislelizumab, is gaining ground as a potential treatment for advanced liver cancer.
Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
JOBS
IN THE PRESS